Advertisement

International Urology and Nephrology

, Volume 48, Issue 8, pp 1291–1304 | Cite as

Hemophagocytic lymphohistiocytosis: an update for nephrologists

  • Edward J. FilipponeEmail author
  • John L. Farber
Nephrology - Review

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome caused by defective lytic capability of cytotoxic T lymphocytes and NK cells, which results in proliferation of benign hemophagocytic histiocytes. A cytokine storm ensues, and a severe systemic inflammatory response syndrome, multiorgan dysfunction syndrome, and death frequently follow. It may occur as a primary (inherited) form, or be acquired secondary to malignancy, infection, rheumatologic disease, or immunosuppression. Cardinal manifestations include fever, cytopenias, hepatosplenomegaly, and dysfunction of liver, kidney, CNS, and/or lung. Additional laboratory findings include marked hyperferritinemia, hypofibrinogenemia, hypertriglyceridemia, abnormal LFTs, coagulopathy, and hyponatremia. Nephrologists need to be aware of this syndrome owing to the frequent occurrence of acute kidney injury in these severely ill patients. Glomerulopathy and nephrotic syndrome may develop. Kidney transplant recipients are at increased risk of HLH due to immunosuppression, and most such cases are triggered by infection with over 50 % mortality. Effective treatment of HLH usually requires chemoimmunotherapy to acutely suppress inflammation, specific treatment of underlying infection or malignancy, and in certain cases hematopoietic stem cell transplantation. The pathogenesis, clinical manifestations, diagnosis, and treatment of HLH are discussed.

Keywords

Hemophagocytic lymphohistiocytosis Macrophage activation syndrome Hemophagocytic syndrome Acute kidney injury Kidney transplantation Systemic inflammatory response syndrome 

Notes

Compliance with ethical standards

Conflict of interest

EJF: speaker’s bureau for Mallinckrodt Pharmaceuticals; JLF: none.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Chandrakasan S, Filipovich AH (2013) Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment. J Pediatr 163(5):1253–1259PubMedCrossRefGoogle Scholar
  2. 2.
    Janka GE, Lehmberg K (2014) Hemophagocytic syndromes—an update. Blood Rev 28(4):135–142PubMedCrossRefGoogle Scholar
  3. 3.
    Brisse E, Wouters CH, Matthys P (2015) Hemophagocytic lymphohistiocytosis (HLH): a heterogeneous spectrum of cytokine-driven immune disorders. Cytokine Growth Factor Rev 26(3):263–280PubMedCrossRefGoogle Scholar
  4. 4.
    Schram AM, Berliner N (2015) How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood 125(19):2908–2914PubMedCrossRefGoogle Scholar
  5. 5.
    Fujiwara FMD, Hibi SMD, Imashuku SMD (1993) Hypercytokinemia in hemophagocytic syndrome. Am J Pediatr Hematol 15(1):92–98CrossRefGoogle Scholar
  6. 6.
    François B, Trimoreau F, Vignon P, Fixe P, Praloran V, Gastinne H (1997) Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med 103(2):114–120PubMedCrossRefGoogle Scholar
  7. 7.
    Strauss Richard Neureiter, Westenburger Daniel, Wehler Bert, Kirchner Markus, Hahn Thomas, Eckhart G, Facp (2004) Multifactorial risk analysis of bone marrow histiocytic hyperplasia with hemophagocytosis in critically ill medical patients-A postmortem clinicopathologic analysis. Crit Care Med 32(6):1316–1321PubMedCrossRefGoogle Scholar
  8. 8.
    Karras A (2009) What nephrologists need to know about hemophagocytic syndrome. Nat Rev Nephrol 5(6):329–336PubMedCrossRefGoogle Scholar
  9. 9.
    Aulagnon F, Lapidus N, Canet E et al (2015) Acute kidney injury in adults with hemophagocytic lymphohistiocytosis. Am J Kidney Dis 65(6):851–859PubMedCrossRefGoogle Scholar
  10. 10.
    Thaunat O, Delahousse M, Fakhouri F et al (2006) Nephrotic syndrome associated with hemophagocytic syndrome. Kidney Int 69(10):1892–1898PubMedCrossRefGoogle Scholar
  11. 11.
    Ponticelli C, Alberighi ODC (2009) Haemophagocytic syndrome—a life-threatening complication of renal transplantation. Nephrol Dial Transplant 24(9):2623–2627PubMedCrossRefGoogle Scholar
  12. 12.
    de Saint Basile G, Ménasché G, Fischer A (2010) Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat Rev Immunol 10(8):568–579CrossRefGoogle Scholar
  13. 13.
    Parvaneh N, Filipovich AH, Borkhardt A (2013) Primary immunodeficiencies predisposed to epstein–barr virus-driven haematological diseases. Br J Haematol 162(5):573–586PubMedCrossRefGoogle Scholar
  14. 14.
    Bode SFN, Ammann S, Al-Herz W et al (2015) The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis. Haematologica 100(7):978–988PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Jessen B, Kögl T, Sepulveda FE, de Saint Basile G, Aichele P, Ehl S (2013) Graded defects in cytotoxicity determine severity of hemophagocytic lymphohistiocytosis in humans and mice. Front Immunol 4:448-1–448-13CrossRefGoogle Scholar
  16. 16.
    Sepulveda FE, Debeurme F, Ménasché G et al (2012) Distinct severity of HLH in both human and murine mutants with complete loss of cytotoxic effector PRF1, RAB27A, and STX11. Blood 121(4):595–603PubMedCrossRefGoogle Scholar
  17. 17.
    Terrell CE, Jordan MB (2013) Mixed hematopoietic or T-cell chimerism above a minimal threshold restores perforin-dependent immune regulation in perforin-deficient mice. Blood 122(15):2618–2621PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Nagafuji K, Nonami A, Kumano T et al (2007) Perforin gene mutations in adult-onset hemophagocytic lymphohistiocytosis. Haematologica 92(7):978–981PubMedCrossRefGoogle Scholar
  19. 19.
    Ueda I, Kurokawa Y, Koike K et al (2007) Late-onset cases of familial hemophagocytic lymphohistiocytosis with missense perforin gene mutations. Am J Hematol 82(6):427–432PubMedCrossRefGoogle Scholar
  20. 20.
    Tesi B, Chiang SC, El-Ghoneimy D et al (2015) Spectrum of atypical clinical presentations in patients with biallelic PRF1 missense mutations. Pediatr Blood Cancer 62(12):2094–2100PubMedCrossRefGoogle Scholar
  21. 21.
    Zhang K, Jordan MB, Marsh RA et al (2011) Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood 118(22):5794–5798PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X (2014) Adult haemophagocytic syndrome. Lancet 383(9927):1503–1516PubMedCrossRefGoogle Scholar
  23. 23.
    Rivière S, Galicier L, Coppo P et al (2014) Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. Am J Med 127(11):1118–1125PubMedCrossRefGoogle Scholar
  24. 24.
    Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP (2014) Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc 89(4):484–492PubMedCrossRefGoogle Scholar
  25. 25.
    Li J, Wang Q, Zheng W et al (2014) Hemophagocytic lymphohistiocytosis: clinical analysis of 103 adult patients. Medicine 93(2):100–105PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Rosario C, Zandman-Goddard G, Meyron-Holtz EG, D’Cruz DP, Shoenfeld Y (2013) The hyperferritinemic syndrome: macrophage activation syndrome, still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med 11:185-7015-11-185CrossRefGoogle Scholar
  27. 27.
    Zoller EE, Lykens JE, Terrell CE et al (2011) Hemophagocytosis causes a consumptive anemia of inflammation. J Exp Med 208(6):1203–1214PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Behrens EM, Canna SW, Slade K et al (2011) Repeated TLR9 stimulation results in macrophage activation syndrome—like disease in mice. J Clin Invest 121(6):2264–2277PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Canna SW, Wrobel J, Chu N, Kreiger PA, Paessler M, Behrens EM (2013) Interferon-γ mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice. Arthritis Rheum 65(7):1764–1775PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Weaver LK, Behrens EM (2014) Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis. Curr Opin Rheumatol 26(5):562–569PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Ohyagi H, Onai N, Sato T et al (2013) Monocyte-derived dendritic cells perform hemophagocytosis to fine-tune excessive immune responses. Immunity 39(3):584–598PubMedCrossRefGoogle Scholar
  32. 32.
    Canna SW, Costa-Reis P, Bernal WE et al (2014) Brief report: alternative activation of laser-captured murine hemophagocytes. Arthritis Rheumatol 66(6):1666–1671PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122(3):787–795PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Schaer CA, Schoedon G, Imhof A, Kurrer MO, Schaer DJ (2006) Constitutive endocytosis of CD163 mediates hemoglobin-heme uptake and determines the noninflammatory and protective transcriptional response of macrophages to hemoglobin. Circ Res 99(9):943–950PubMedCrossRefGoogle Scholar
  35. 35.
    Schaer DJ, Schaer CA, Schoedon G, Imhof A, Kurrer MO (2006) Hemophagocytic macrophages constitute a major compartment of heme oxygenase expression in sepsis. Eur J Haematol 77(5):432–436PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Otterbein LE, Soares MP, Yamashita K, Bach FH (2003) Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol 24(8):449–455PubMedCrossRefGoogle Scholar
  37. 37.
    Minoia F, Davì S, Horne A et al (2014) Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol 66(11):3160–3169PubMedCrossRefGoogle Scholar
  38. 38.
    Kumakura S, Murakawa Y (2014) Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults. Arthritis Rheum 66(8):2297–2307CrossRefGoogle Scholar
  39. 39.
    Parodi A, Davì S, Pringe AB et al (2009) Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum 60(11):3388–3399PubMedCrossRefGoogle Scholar
  40. 40.
    Lambotte O, Khellaf M, Harmouche H et al (2006) Characteristics and long-term outcome of 15 episodes of systemic lupus erythematosus-associated hemophagocytic syndrome. Medicine 85(3):169–182. Accessed 6 Jan 2016Google Scholar
  41. 41.
    Behrens EM, Beukelman T, Paessler M, Cron RQ (2007) Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 34(5):1133–1138PubMedGoogle Scholar
  42. 42.
    Bleesing J, Prada A, Siegel DM et al (2007) The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor α-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 56(3):965–971PubMedCrossRefGoogle Scholar
  43. 43.
    Reddy VV, Myles A, Cheekatla SS, Singh S, Aggarwal A (2014) Soluble CD25 in serum: a potential marker for subclinical macrophage activation syndrome in patients with active systemic onset juvenile idiopathic arthritis. Int J Rheum Dis 17(3):261–267PubMedCrossRefGoogle Scholar
  44. 44.
    Villanueva J, Lee S, Giannini EH et al (2005) Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 7(1):R30–R37PubMedCrossRefGoogle Scholar
  45. 45.
    Ishii E, Ohga S, Imashuku S et al (2007) Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 86(1):58–65PubMedCrossRefGoogle Scholar
  46. 46.
    Voskoboinik I, Thia M, Trapani JA (2005) A functional analysis of the putative polymorphisms A91V and N252S and 22 missense perforin mutations associated with familial hemophagocytic lymphohistiocytosis. Blood 105(12):4700–4706PubMedCrossRefGoogle Scholar
  47. 47.
    Zhang K, Chandrakasan S, Chapman H et al (2014) Synergistic defects of different molecules in the cytotoxic pathway lead to clinical familial hemophagocytic lymphohistiocytosis. Blood 124(8):1331–1334PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Sieni E, Cetica V, Piccin A et al (2012) Familial hemophagocytic lymphohistiocytosis may present during adulthood: clinical and genetic features of a small series. PLoS ONE 7(9):e44649PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Wang Y, Wang Z, Zhang J et al (2014) Genetic features of late onset primary hemophagocytic lymphohistiocytosis in adolescence or adulthood. PLoS ONE 9(9):e107386PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Zhang K, Biroschak J, Glass DN et al (2008) Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum 58(9):2892–2896PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Vastert SJ, van Wijk R, D’Urbano LE et al (2010) Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology 49(3):441–449PubMedCrossRefGoogle Scholar
  52. 52.
    Kaufman KM, Linghu B, Szustakowski JD et al (2014) Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol 66(12):3486–3495PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Zhang M, Behrens E, Atkinson TP, Shakoory B, Grom A, Cron R (2014) Genetic defects in cytolysis in macrophage activation syndrome. Curr Rheumatol Rep 16(9):1–8CrossRefGoogle Scholar
  54. 54.
    Horne A, Trottestam H, Aricò M et al (2008) Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis. Br J Haematol 140(3):327–335. doi: 10.1111/j.1365-2141.2007.06922.x PubMedCrossRefGoogle Scholar
  55. 55.
    Trottestam H, Horne A, Aricò M et al (2011) Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood 118(17):4577–4584PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Deiva K, Mahlaoui N, Beaudonnet F et al (2012) CNS involvement at the onset of primary hemophagocytic lymphohistiocytosis. Neurology 78(15):1150–1156PubMedCrossRefGoogle Scholar
  57. 57.
    Gratton SM, Powell TR, Theeler BJ, Hawley JS, Amjad FS, Tornatore C (2015) Neurological involvement and characterization in acquired hemophagocytic lymphohistiocytosis in adulthood. J Neurol Sci 357(1–2):136–142PubMedCrossRefGoogle Scholar
  58. 58.
    Valade S, Azoulay E, Galicier L et al (2015) Coagulation disorders and bleedings in critically ill patients with hemophagocytic lymphohistiocytosis. Medicine 94(40):e1692PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Chen J, Fleming MD, Pinkus GS et al (2010) Pathology of the liver in familial hemophagocytic lymphohistiocytosis. Am J Surg Pathol 34(6):852–867PubMedCrossRefGoogle Scholar
  60. 60.
    Morrell DS, Pepping MA, Scott JP, Esterly NB, Drolet BA (2002) Cutaneous manifestations of hemophagocytic lymphohistiocytosis. Arch Dermatol 138(9):1208–1212PubMedCrossRefGoogle Scholar
  61. 61.
    Kerl K, Wolf IH, Cerroni L, Wolf P, French LE, Kerl H (2015) Hemophagocytosis in cutaneous autoimmune disease. Am J Dermatopathol 37(7):539–543PubMedCrossRefGoogle Scholar
  62. 62.
    Castillo L, Carcillo J (2009) Secondary hemophagocytic lymphohistiocytosis and severe sepsis/systemic inflammatory response syndrome/multiorgan dysfunction syndrome/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation. Pediatr Crit Care Med 10(3):387–392PubMedCrossRefGoogle Scholar
  63. 63.
    Malaga-Dieguez L, Ming W, Trachtman H (2015) Direct reversible kidney injury in familial hemophagocytic lymphohistiocytosis type 3. J Am Soc Nephrol 26(8):1777–1780PubMedCrossRefGoogle Scholar
  64. 64.
    Landau D, Gurevich E, Kapelushnik J, Tamary H, Shelef I, Lazar I (2013) Association between childhood nephrotic syndrome and hemophagocytic lymphohistiocytosis. Pediatr Nephrol 28(12):2389–2392PubMedCrossRefGoogle Scholar
  65. 65.
    Risdall RJ, McKenna RW, Nesbit ME et al (1979) Virus-associated hemophagocytic syndrome A benign histiocytic proliferation distinct from malignant histiocytosis. Cancer 44(3):993–1002PubMedCrossRefGoogle Scholar
  66. 66.
    Karras A, Thervet E, Legendre C, for the Groupe Cooperatif de transplantation d’Ile de France (2004) Hemophagocytic syndrome in renal transplant recipients: report of 17 cases and review of literature. Transplantation 77(2):238–243PubMedCrossRefGoogle Scholar
  67. 67.
    Asci G, Toz H, Ozkahya M et al (2006) High-dose immunoglobulin therapy in renal transplant recipients with hemophagocytic histiocytic syndrome. J Nephrol 19(3):322–326PubMedGoogle Scholar
  68. 68.
    Lo MM, Mo JQ, Dixon BP, Czech KA (2010) Disseminated histoplasmosis associated with hemophagocytic lymphohistiocytosis in kidney transplant recipients. Am J Transplant 10(3):687–691PubMedCrossRefGoogle Scholar
  69. 69.
    Raffray L, Couzi L, Viallard JF et al (2010) Mycophenolate mofetil: a possible cause of hemophagocytic syndrome following renal transplantation? Am J Transplant 10(10):2378–2379PubMedCrossRefGoogle Scholar
  70. 70.
    Tangnararatchakit K, Tirapanich W, Tapaneya-Olarn W et al (2012) Severe nonfebrile dengue infection in an adolescent after postoperative kidney transplantation: a case report. Transplant Proc 44(1):303–306PubMedCrossRefGoogle Scholar
  71. 71.
    Grabas M, Darrieux L, Potier J, Safa G (2012) Hemophagocytic syndrome as the presenting manifestation of bacillary angiomatosis in a renal transplant recipient. J Am Acad Dermatol 67(5):e236–e237PubMedCrossRefGoogle Scholar
  72. 72.
    Yaich S, Charfeddine K, Hsairi D et al (2014) BK virus-associated hemophagocytic syndrome in a renal transplant recipient. Saudi J Kidney Dis Transplant 25(3):610–614CrossRefGoogle Scholar
  73. 73.
    Wisanuyotin S, Jiravuttipong A, Puapairoj A (2014) De novo lupus nephritis in a renal transplanted child: a case report. Transplant Proc 46(2):648–650PubMedCrossRefGoogle Scholar
  74. 74.
    Poudel A, Lew J, Slayton W, Dharnidharka VR (2014) Bartonella henselae infection inducing hemophagocytic lymphohistiocytosis in a kidney transplant recipient. Pediatr Transplant 18(3):E83–E87PubMedCrossRefGoogle Scholar
  75. 75.
    Broeckaert-van Orshoven A, Michielsen P, Vandepitte J (1979) Fatal leishmaniasis in renal-transplant patient. Lancet 314(8145):740–741CrossRefGoogle Scholar
  76. 76.
    Reiner AP, Spivak JL, Dietz N (1988) Hematophagic histiocytosis: a report of 23 new patients and a review of the literature. Medicine 67(6):369–388PubMedCrossRefGoogle Scholar
  77. 77.
    Calonge VM, Glotz D, Bouscary D et al (1995) Hemophagocytic histiocytosis (HH) in renal transplant recipients under cyclosporin therapy: report of the first two cases. Clin Transplant 9(2):88–91PubMedGoogle Scholar
  78. 78.
    Slovut DP, Benedetti E, Matas AJ (1996) Babesiosis and hemophagocytic syndrome in an asplenic renal transplant recipient. Transplantation 62(4):537–539PubMedCrossRefGoogle Scholar
  79. 79.
    Kursat S, Cagirgan S, Ok E et al (1997) Haemophagocytic–histiocytic syndrome in renal transplantation. Nephrol Dial Transplant 12(5):1058–1060PubMedCrossRefGoogle Scholar
  80. 80.
    Dargent J, Vermylen P, Abramowicz D et al (1997) Disseminated angiosarcoma presenting as a hemophagocytic syndrome in a renal allograft recipient. Transplant Int 10(1):61–64CrossRefGoogle Scholar
  81. 81.
    Peeters P, Sennesael J, De Raeve H, De Waele M, Verbeelen D (1997) Hemophagocytic syndrome and T-cell lymphoma after kidney transplantation: a case report. Transplant Int 10(6):471–474CrossRefGoogle Scholar
  82. 82.
    Rossi C, Delforge M-, Jacobs F et al (2001) Fatal primary infection due to human herpesvirus 6 variant A in a renal transplant recipient. Transplantation 71(2):288–292PubMedCrossRefGoogle Scholar
  83. 83.
    Luppi M, Barozzi P, Rasini V et al (2002) Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet. Transplantation 74(1):131–133PubMedCrossRefGoogle Scholar
  84. 84.
    Gurkan A, Yakupoglu U, Yavuz A et al (2006) Hemophagocytic syndrome in kidney transplant recipients: report of four cases from a single center. Acta Haematol 116(2):108–113. Accessed 29 Nov 2015Google Scholar
  85. 85.
    Hot A, Madoux MHG, Viard JP, Coppéré B, Ninet J (2008) Successful treatment of cytomegalovirus-associated hemophagocytic syndrome by intravenous immunoglobulins. Am J Hematol 83(2):159–162PubMedCrossRefGoogle Scholar
  86. 86.
    Bossini N, Sandrini S, Setti G et al (2005) Successful treatment with liposomal doxorubicin and Foscarnet in a patient with widespread Kaposi’s sarcoma and human herpes virus 8-related, serious hemophagocytic syndrome, after renal transplantation. G Ital Nefrol 22(3):281–286PubMedGoogle Scholar
  87. 87.
    Esposito L, Hirsch H, Basse G, Fillola G, Kamar N, Rostaing L (2007) BK virus-related hemophagocytic syndrome in a renal transplant patient [3]. Transplantation 83(3):365PubMedCrossRefGoogle Scholar
  88. 88.
    Segall L, Moal M, Doucet L, Kergoat N, Bourbigot B (2006) Toxoplasmosis-associated hemophagocytic syndrome in renal transplantation. Transplant Int 19(1):78–80CrossRefGoogle Scholar
  89. 89.
    González-Posada JM, Hernández D, Martin A et al (2008) Hemophagocytic lymphohistiocytosis in a pancreas-kidney transplant recipient: response to dexamethasone and cyclosporine. Clin Nephrol 70(1):82–86PubMedCrossRefGoogle Scholar
  90. 90.
    Ardalan MR, Shoja MM, Tubbs RS, Esmaili H, Keyvani H (2008) Postrenal transplant hemophagocytic lymphohistiocytosis and thrombotic microangiopathy associated with parvovirus B19 infection. Am J Transplant 8(6):1340–1344PubMedCrossRefGoogle Scholar
  91. 91.
    Henter J, Horne A, Aricó M et al (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124–131PubMedCrossRefGoogle Scholar
  92. 92.
    Hejblum G, Lambotte O, Galicier L et al (2014) A web-based delphi study for eliciting helpful criteria in the positive diagnosis of hemophagocytic syndrome in adult patients. PLoS One 9(4):e94024-1–e94024-6CrossRefGoogle Scholar
  93. 93.
    Fardet L, Galicier L, Lambotte O et al (2014) Development and validation of the hscore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 66(9):2613–2620PubMedCrossRefGoogle Scholar
  94. 94.
    Ravelli A, Magni-Manzoni S, Pistorio A et al (2005) Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 146(5):598–604PubMedCrossRefGoogle Scholar
  95. 95.
    Davì S, Minoia F, Pistorio A et al (2014) Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Arthritis Rheumatol 66(10):2871–2880PubMedCrossRefGoogle Scholar
  96. 96.
    Lehmberg K, Pink I, Eulenburg C, Beutel K, Maul-Pavicic A, Janka G (2013) Differentiating macrophage activation syndrome in systemic juvenile idiopathic arthritis from other forms of hemophagocytic lymphohistiocytosis. J Pediatr 162(6):1245–1251PubMedCrossRefGoogle Scholar
  97. 97.
    Allen CE, Yu X, Kozinetz CA, McClain KL (2008) Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 50(6):1227–1235PubMedCrossRefGoogle Scholar
  98. 98.
    Moore C Jr, Ormseth M, Fuchs H (2013) Causes and significance of markedly elevated serum ferritin levels in an academic medical center. JCR: J Clin Rheumatol 19(6):324–328PubMedGoogle Scholar
  99. 99.
    Beer T, Vadakara J (2015) Etiologies and short-term mortality in patients with ultraelevated serum ferritin. South Med J 108(9):574–578PubMedCrossRefGoogle Scholar
  100. 100.
    Schram AM, Campigotto F, Mullally A et al (2015) Marked hyperferritinemia does not predict for HLH in the adult population. Blood 125(10):1548–1552PubMedCrossRefGoogle Scholar
  101. 101.
    Gupta A, Tyrrell P, Valani R, Benseler S, Weitzman S, Abdelhaleem M (2008) The role of the initial bone marrow aspirate in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 51(3):402–404PubMedCrossRefGoogle Scholar
  102. 102.
    Goel S, Polski JM, Imran H (2012) Sensitivity and specificity of bone marrow hemophagocytosis in hemophagocytic lymphohistiocytosis. Ann Clin Lab Sci 42(1):21–25PubMedGoogle Scholar
  103. 103.
    Listinsky CM (1988) Common reactive erythrophagocytosis in axillary lymph nodes. Am J Clin Pathol 90(2):189–192PubMedCrossRefGoogle Scholar
  104. 104.
    Suster S, Hilsenbeck S, Rywlin AM (1988) Reactive histiocytic hyperplasia with hemophagocytosis in hematopoietic organs: a reevaluation of the benign hemophagocytic proliferations. Hum Pathol 19(6):705–712PubMedCrossRefGoogle Scholar
  105. 105.
    Lehmberg K, Ehl S (2013) Diagnostic evaluation of patients with suspected haemophagocytic lymphohistiocytosis. Br J Haematol 160(3):275–287PubMedCrossRefGoogle Scholar
  106. 106.
    Bryceson YT, Pende D, Maul-Pavicic A et al (2012) A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood 119(12):2754–2763PubMedCrossRefGoogle Scholar
  107. 107.
    Koh K, Im HJ, Chung N et al (2015) Clinical features, genetics, and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in Korea: report of a nationwide survey from Korea histiocytosis working party. Eur J Haematol 94(1):51–59PubMedCrossRefGoogle Scholar
  108. 108.
    Rouphael NG, Talati NJ, Vaughan C, Cunningham K, Moreira R, Gould C (2007) Infections associated with haemophagocytic syndrome. Lancet Infect Dis 7(12):814–822PubMedCrossRefGoogle Scholar
  109. 109.
    Lehmberg K, Nichols KE, Henter J- et al (2015) Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. Haematologica 100(8):997–1004PubMedGoogle Scholar
  110. 110.
    Janka GE (1983) Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr 140(3):221–230. Accessed 4 Jan 2016Google Scholar
  111. 111.
    Mahlaoui N, Ouachée-Chardin M, de Saint Basile G et al (2007) Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics 120(3):e622–e628PubMedCrossRefGoogle Scholar
  112. 112.
    Johnson TS, Terrell CE, Millen SH, Katz JD, Hildeman DA, Jordan MB (2014) Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J Immunol 192(1):84–91PubMedCrossRefGoogle Scholar
  113. 113.
    Arca M, Fardet L, Galicier L et al (2015) Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide. Br J Haematol 168(1):63–68PubMedCrossRefGoogle Scholar
  114. 114.
    Imashuku S, Kuriyama K, Teramura T et al (2001) Requirement for etoposide in the treatment of epstein–barr virus—associated hemophagocytic lymphohistiocytosis. J Clin Oncol 19(10):2665–2673PubMedGoogle Scholar
  115. 115.
    Imashuku S, Kuriyama K, Sakai R et al (2003) Treatment of epstein–barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in young adults: a report from the HLH studyl center. Med Pediatr Oncol 41(2):103–109PubMedCrossRefGoogle Scholar
  116. 116.
    Su IJ, Chen RL, Lin DT, Lin KS, Chen CC (1994) Epstein–barr virus (EBV) infects T lymphocytes in childhood EBV-associated hemophagocytic syndrome in taiwan. Am J Pathol 144(6):1219–1225PubMedPubMedCentralGoogle Scholar
  117. 117.
    Beutel K, Gross-Wieltsch U, Wiesel T, Stadt UZ, Janka G, Wagner H (2009) Infection of T lymphocytes in epstein–barr virus-associated hemophagocytic lymphohistiocytosis in children of non-asian origin. Pediatr Blood Cancer 53(2):184–190PubMedCrossRefGoogle Scholar
  118. 118.
    Kikuta H, Sakiyama Y (1995) Etoposide (VP-16) inhibits epstein–barr virus determined nuclear antigen (EBNA) synthesis. Br J Haematol 90(4):971–972PubMedCrossRefGoogle Scholar
  119. 119.
    Kasahara Y, Yachie A (2002) Cell type specific infection of epstein–barr virus (EBV) in EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Crit Rev Oncol 44(3):283–294CrossRefGoogle Scholar
  120. 120.
    Chellapandian D, Das R, Zelley K et al (2013) Treatment of epstein barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol 162(3):376–382PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Ohga S, Kudo K, Ishii E et al (2010) Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and epstein–barr virus-associated hemophagocytic lymphohistiocytosis in japan. Pediatr Blood Cancer 54(2):299–306PubMedGoogle Scholar
  122. 122.
    Buyse S, Teixeira L, Galicier L et al (2010) Critical care management of patients with hemophagocytic lymphohistiocytosis. Intensive Care Med 36(10):1695–1702PubMedCrossRefGoogle Scholar
  123. 123.
    Barba T, Maucort-Boulch D, Iwaz J et al (2015) Hemophagocytic lymphohistiocytosis in intensive care unit: a 71-case strobe-compliant retrospective study. Medicine 94(51):e2318PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Carcillo JA, Simon DW, Podd BS (2015) How we manage hyperferritinemic sepsis-related multiple organ dysfunction syndrome/macrophage activation syndrome/secondary hemophagocytic lymphohistiocytosis histiocytosis. Pediatr Crit Care Med 16(6):598–600PubMedCrossRefGoogle Scholar
  125. 125.
    Demirkol D, Yildizdas D, Bayrakci B et al (2012) Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment? Crit Care 16(2):R52PubMedPubMedCentralCrossRefGoogle Scholar
  126. 126.
    Rajasekaran S, Kruse K, Kovey K et al (2014) Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children. Pediatr Crit Care Med 15(5):401–408PubMedCrossRefGoogle Scholar
  127. 127.
    Opal SM, Fisher CJ Jr, Dhainaut J-A et al (1997) Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 25(7):1115–1124PubMedCrossRefGoogle Scholar
  128. 128.
    Lehmberg K, Sprekels B, Nichols KE et al (2015) Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents. Br J Haematol 170(4):539–549PubMedCrossRefGoogle Scholar
  129. 129.
    Mánard F, Besson C, Rincá P et al (2008) Hodgkin lymphoma—associated hemophagocytic syndrome: a disorder strongly correlated with epstein–barr virus. Clin Infect Dis 47(4):531–534CrossRefGoogle Scholar
  130. 130.
    Fardet L, Lambotte O, Meynard J et al (2010) Reactive haemophagocytic syndrome in 58 HIV-1-infected patients: clinical features, underlying diseases and prognosis. AIDS 24(9):1299–1306PubMedCrossRefGoogle Scholar
  131. 131.
    Minoia F, Davì S, Horne A et al (2014) Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol 66(11):3160–3169PubMedCrossRefGoogle Scholar
  132. 132.
    De Benedetti F, Brunner HI, Ruperto N et al (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. New Engl J Med 367(25):2385–2395PubMedCrossRefGoogle Scholar
  133. 133.
    Yokota S, Itoh Y, Morio T, Sumitomo N, Daimaru K, Minota S (2015) Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol 42(4):712–722PubMedCrossRefGoogle Scholar
  134. 134.
    Ruperto N, Brunner HI, Quartier P et al (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. New Engl J Med 367(25):2396–2406PubMedCrossRefGoogle Scholar
  135. 135.
    Nigrovic PA, Mannion M, Prince FHM et al (2011) Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63(2):545–555PubMedCrossRefGoogle Scholar
  136. 136.
    Boehler A, Schaffner A, Salomon F, Keusch G (1994) Cytomegalovirus disease of late onset following renal transplantation: a potentially fatal entity. Scand J Infect Dis 26(4):369–373. Accessed 29 Nov 2015Google Scholar
  137. 137.
    Rostaing L, Fillola G, Baron E, Cisterne JM, Durand D (1995) Course of hemophagocytic histiocytic syndrome in renal transplant patients. Transplantation 60(5):506–509PubMedCrossRefGoogle Scholar
  138. 138.
    Drut R, Drut RM (1994) EBV-associated kaposi’s sarcoma in a pediatric renal transplant recipient. Fetal Pediatr Pathol 14(5):863–872CrossRefGoogle Scholar
  139. 139.
    Gupta P, Hurley RW, Helseth PH, Goodman JL, Hammerschmidt DE (1995) Pancytopenia due to hemophagocytic syndrome as the presenting manifestation of babesiosis. Am J Hematol 50(1):60–62PubMedCrossRefGoogle Scholar
  140. 140.
    Ravelli A, Minoia F, Davi S et al (2016) 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative. Ann Rheum Dis 75 (3):481–489PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2016

Authors and Affiliations

  1. 1.Division of Nephrology, Department of Medicine, Sydney Kimmel School of MedicineThomas Jefferson UniversityPhiladelphiaUSA
  2. 2.Department of Pathology, Sydney Kimmel School of MedicineThomas Jefferson UniversityPhiladelphiaUSA
  3. 3.PhiladelphiaUSA

Personalised recommendations